Nemolizumab monotherapy improves itch, sleep disturbance, and skin lesions in patients with moderate-to-severe prurigo nodularis: Pooled analyses from OLYMPIA 1 and OLYMPIA 2 phase 3 studies

被引：0
|
作者：
Yosipovitch, Gil [1 ]
Staender, Sonja [2 ]
Metz, Martin [3 ]
Pink, Andrew E. [4 ]
Silverberg, Jonathan, I [5 ]
Sofen, Howard [6 ]
Ahmed, Faiz [7 ]
Noda, Aliene [8 ]
Lopez, Zarif K. Jabbar [8 ]
Piketty, Christophe [8 ]
Kwatra, Shawn G. [9 ,10 ]
机构：
[1] Univ Miami, Miami Itch Ctr, Miller Sch Med, Miami, FL USA
[2] Univ Hosp Munster, Ctr Chron Pruritus, Munster, Germany
[3] Charite, Inst Allergol, Berlin, Germany
[4] Guys & St Thomas NHS Fdn Trust, St Johns Inst Dermatol, London, England
[5] George Washington Univ, Sch Med & Hlth Sci, Washington, DC USA
[6] UCLA, Sch Med, Dept Med Dermatol, Los Angeles, CA USA
[7] Galderma Labs, Dallas, TX USA
[8] Galderma R&D, Zug, Switzerland
[9] Univ Maryland, Sch Med, Dept Dermatol, Baltimore, MD USA
[10] Univ Maryland, Maryland Itch Ctr, Sch Med, Baltimore, MD USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 191卷
关键词：
efficacy; nemolizumab; prurigo nodularis; pruritus; safety; TRIAL;
D O I：
10.1093/bjd/ljae266.046
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
672
引用
收藏
页码：47 / 48
页数：2
相关论文
共 50 条
  • [31] Efficacy and safety of oral tofacitinib in North American patients with moderate to severe plaque psoriasis: Pooled analyses of data from randomized phase 3 studies
    Korman, Neil J.
    King, Brett
    Wolk, Robert
    Tan, Huaming
    Kaur, Mandeep
    Robertson, Debbie
    Langley, Richard
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB247 - AB247
  • [32] Ixekizumab treatment improves skin-related sexual difficulties in patients with moderate-to-severe plaque psoriasis: integrated results from three Phase 3 trials (UNCOVER-1,-2 and-3)
    Guenther, L. C.
    Foley, P.
    Cather, J.
    Bleakman, A. Potts
    Burge, R.
    Zhu, B.
    van de Kerkhof, P.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 79 - 80
  • [33] Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies
    Reich, K.
    Papp, K. A.
    Armstrong, A. W.
    Wasfi, Y.
    Li, S.
    Shen, Y. K.
    Randazzo, B.
    Song, M.
    Kimball, A. B.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 180 (05) : 1039 - 1049
  • [34] Indacaterol/glycopyrrolate Significantly Improves Health Status And Dyspnea In Different Subgroups Of Patients With Moderate-To-Severe COPD: Pooled Analysis Of Flight1 And Flight2 Studies
    Mahler, D. A.
    Donohue, J. F.
    Fucile, S.
    Yadao, A.
    Maitra, S.
    Taylor, A. Fowler
    Fogel, R.
    Patalano, F.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [35] Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials
    Lebwohl, Mark
    Leonardi, Craig
    Griffiths, Christopher E. M.
    Prinz, Joerg C.
    Szapary, Philippe O.
    Yeilding, Newman
    Guzzo, Cynthia
    Li, Shu
    Hsu, Ming-Chun
    Strober, Bruce
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (05) : 731 - 741
  • [36] Glycopyrronium Demonstrates Significant Improvements in Lung Function in Patients With Moderate-to-Severe COPD: Pooled Analysis From the GEM1 and GEM2 Studies
    Kerwin, Edward
    Spangenthal, Selwyn
    Miller, S. David
    D'Andrea, Peter
    Henley, Michelle
    Eckert, Joerg H.
    Patalano, Francesco
    CHEST, 2015, 148 (04)
  • [37] Indacaterol/glycopyrrolate Significantly Improves COPD Assessment Test (cat) Scores In Us Patients With Moderate-To-Severe COPD: Subgroup Analysis From Pooled Flight1 And Flight2 Studies
    Fogel, R.
    Maitra, S.
    Patalano, F.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [38] Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2)
    Thaci, Diamant
    Simpson, Eric L.
    Deleuran, Mette
    Kataoka, Yoko
    Chen, Zhen
    Gadkari, Abhijit
    Eckert, Laurent
    Akinlade, Bolanle
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Ardeleanu, Marius
    JOURNAL OF DERMATOLOGICAL SCIENCE, 2019, 94 (02) : 266 - 275
  • [39] Achieving incrementally greater skin improvement thresholds with upadacitinib in moderate-to-severe atopic dermatitis: a pooled analysis of two phase III studies (Measure Up 1 and Measure Up 2)
    Reich, K.
    Langley, R. G.
    Calimlim, B. M.
    Teixeira, H. D.
    Zeng, J.
    Silverberg, J. I.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E131 - E132
  • [40] Dupilumab reduces the number of lesions in adult patients with prurigo nodularis presenting with multiple lesion morphologies: pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2)
    Stander, Sonja
    Yosipovitch, Gil
    Kim, Brian S.
    Hong, H. Chih-ho
    Metz, Martin
    Murota, Hiroyuki
    Gao, Xing-Hua
    de Bruin-Weller, Marjolein
    Praestgaard, Amy
    Zahn, Joseph
    Wiggins, Simmi
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : 93 - 94
12345